Drug General Information
Drug ID
D08NMV
Former ID
DNCL003697
Drug Name
Ixekizumab
Synonyms
LY2439821
Drug Type
Monoclonal antibody
Indication Plaque psoriasis [ICD10:L00-L99] Approved [889440]
Psoriatic arthritis [ICD9: 696; ICD10:L40.5, M07] Phase 3 [523694], [542543]
Company
Eli Lilly
Target and Pathway
Target(s) Interleukin-17 Target Info Modulator [532056], [532704]
KEGG Pathway Cytokine-cytokine receptor interaction
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database IL27-mediated signaling events
IL23-mediated signaling events
WikiPathways TCR Signaling Pathway
Allograft Rejection
IL17 signaling pathway
References
Ref 523694ClinicalTrials.gov (NCT01474512) A Phase 3 Study in Participants With Moderate to Severe Psoriasis. U.S. National Institutes of Health.
Ref 542543(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7541).
Ref 8894402016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. doi: 10.1038/nrd.2017.14.
Ref 532056Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
Ref 532704A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response totumor necrosis factor inhibitors. Arthritis Rheumatol. 2014 Jul;66(7):1693-704.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.